Silvia Zappavigna

7.1k citations
100 papers · 3.6k indexed · 2 hit papers · h-index 35

Silvia Zappavigna

98 papers receiving 3.5k citations

Hit Papers

Anti-Inflammatory Drugs as Anticancer Agents2872019202620212023100200300400

Peers

Silvia Zappavigna
Comparison fields: 5 of 130
  • Cancer Research 856
  • Oncology 805
  • Molecular Biology 1.7k
  • Biomaterials 295
  • Pharmacology 255
Replace Ling Dong with:
Ling Dong China
Massimo Donadelli Italy
S. Asha Nair India
Min Zhang China
Ke Xu China
Antônio Barbieri Italy
Mohammad H. Pourgholami Australia
Thomas C. Chen United States
Emilia Wiecheć Sweden
Xi Yang China
Silvia Zappavigna relative to Ling Dong China Ling Dong's profile →
Citations per field
00.5×1.5×2.2×
Ling Dong · 1×
Citations per year

Countries citing papers authored by Silvia Zappavigna

Since Specialization
Citations

This map shows the geographic impact of Silvia Zappavigna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Zappavigna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Zappavigna more than expected).

Fields of papers citing papers by Silvia Zappavigna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Zappavigna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Zappavigna. The network helps show where Silvia Zappavigna may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Silvia Zappavigna, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Silvia Zappavigna Line = papers co-authored together Silvia Zappavigna links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20241
2 20249
3 202320
4 20235
5 20228
6 20225
7 20225
8 202211
9 202036
10 201925
11 201915
12 201811
13 201634
14 201516
15 2015122
16 201333
17 201319
18 201342
19 2012107
20 201053

About Silvia Zappavigna

Silvia Zappavigna is a scholar working on Cancer Research, Oncology and Biomaterials, having authored 100 papers that have together received 3.6k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (14 papers), Cancer-related molecular mechanisms research (14 papers), Nanoparticle-Based Drug Delivery (10 papers), Radiopharmaceutical Chemistry and Applications (9 papers), Bone health and treatments (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and RNA modifications and cancer (7 papers). The work is most often cited by research in Cancer Research (856 citations), Oncology (805 citations) and Molecular Biology (1.7k citations). Silvia Zappavigna has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Michele Caraglia, Anna Grimaldi, Amalia Luce, Gabriella Misso, Angela Lombardi, Alessia Maria Cossu, Marianna Abate, Marco Bocchetti, Carlo Irace and Giuseppe De Rosa. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026